AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23280432 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SIT)
Number of subjects: 32
Study 21885491 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept plus methotrexate (MTX)
Number of subjects: 0
Study 19128717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem walking at preferred cadence with Swaystar accelerometer
Number of subjects: 15
Study 19128717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem walking at 75% of preferred cadence with Swaystar accelerometer
Number of subjects: 15
Study 19128717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem walking at 125% of preferred cadence with Swaystar accelerometer
Number of subjects: 15
Study 16579323 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Plans (RPPs)
Number of subjects: 0
Study 16579323 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study 12692541 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous recessive for the FUT2 gene (non-expressors of H type-1 oligosaccharide)
Number of subjects: 0
Study 12692541 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional FUT2 gene (susceptible population)
Number of subjects: 0
Study 10582197 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil sodium 4 mg b.i.d. (two times daily)
Number of subjects: 38
Study 10582197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg q.i.d. (four times daily)
Number of subjects: 38
Study 10582197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7788003 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil treatment
Number of subjects: 25
Study 7788003 — intervention group
Group type: COMPARATOR
Intervention: Control (euthyroid patients with simple diffuse goiter)
Number of subjects: 25
Study 2195937 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (budesonide 200 micrograms twice a day)
Number of subjects: 22
Study 2195937 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators (terbutaline 250 micrograms, two puffs four times a day)
Number of subjects: 22
Study 2195937 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 22
Study 2195937 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators (Group A)
Number of subjects: 22
Study 2195937 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (Group B)
Number of subjects: 22
Study 310249 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunting
Number of subjects: 0
Study 310249 — intervention group
Group type: COMPARATOR
Intervention: Mesocaval shunting
Number of subjects: 0
Study 31719096 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education visits for 12 months
Number of subjects: 212
Study 31719096 — intervention group
Group type: COMPARATOR
Intervention: Usual T1D care
Number of subjects: 212
Study 29118299 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol)
Number of subjects: 845
Study 29118299 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT; aspirin and clopidogrel)
Number of subjects: 845
Study 24817596 — intervention group
Group type: EXPERIMENTAL
Intervention: White rice with chicken breast
Number of subjects: 12
Study 24817596 — intervention group
Group type: EXPERIMENTAL
Intervention: White rice with ground nut oil
Number of subjects: 12
Study 24817596 — intervention group
Group type: EXPERIMENTAL
Intervention: White rice with leafy vegetable
Number of subjects: 12
Study 24817596 — intervention group
Group type: EXPERIMENTAL
Intervention: White rice with chicken, oil, and vegetable
Number of subjects: 12
Study 24817596 — intervention group
Group type: COMPARATOR
Intervention: White rice alone
Number of subjects: 12
Study 24817596 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution (reference food)
Number of subjects: 12
Study 24817596 — intervention group
Group type: EXPERIMENTAL
Intervention: White rice with vegetable
Number of subjects: 12
Study 22569355 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin population pharmacokinetics
Number of subjects: 56
Study 20144366 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Connected Health (DCH) program - online application for glucose monitoring
Number of subjects: 7
Study 17803575 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC + CBC
Number of subjects: 40
Study 17803575 — intervention group
Group type: COMPARATOR
Intervention: CBC
Number of subjects: 40
Study 15007565 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and FDG PET imaging
Number of subjects: 101
Study 11952478 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using verteporfin
Number of subjects: 0
Study 11952478 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpupillary thermotherapy (TTT)
Number of subjects: 0
Study 11952478 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factor (VEGF) agents
Number of subjects: 0
Study 9465361 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention (Working Well Trial)
Number of subjects: 40
Study 9465361 — intervention group
Group type: COMPARATOR
Intervention: Control worksites
Number of subjects: 40
Study 7614522 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef 200 mg BID
Number of subjects: 209
Study 7614522 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef 400 mg BID
Number of subjects: 209
Study 2645756 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg once daily
Number of subjects: 3
Study 2645756 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg once daily
Number of subjects: 3
Study 2645756 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 40 mg once daily
Number of subjects: 3
Study 2645756 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 80 mg once daily
Number of subjects: 3
Study 2645756 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 3
Study 2645756 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 3
Study 495045 — intervention group
Group type: EXPERIMENTAL
Intervention: hypertonic glycerol infusion plus dexamethasone
Number of subjects: 93
Study 495045 — intervention group
Group type: COMPARATOR
Intervention: dexamethasone alone
Number of subjects: 93
Study 31784097 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Zadek Osteotomy (ZO)
Number of subjects: 26
Study 30939398 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive n-back training (n = 11)
Number of subjects: 21
Study 30939398 — intervention group
Group type: COMPARATOR
Intervention: Less potent 1-back training (n = 10)
Number of subjects: 21
Study 27696616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.1 mmol/kg)
Number of subjects: 60
Study 26103528 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g intravenous cefazolin
Number of subjects: 26
Study 26103528 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g intravenous cefazolin
Number of subjects: 26
Study 26103528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 2 g and 3 g intravenous cefazolin
Number of subjects: 26
Study 23644855 — intervention group
Group type: EXPERIMENTAL
Intervention: glutamine+zinc+vitamin A
Number of subjects: 167
Study 23644855 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 167
Study 21875678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinovial(®) (16 mg/2 ml, 0.8% highly purified intra-articular hyaluronic acid)
Number of subjects: 381
Study 21875678 — intervention group
Group type: COMPARATOR
Intervention: Synvisc(®) (16 mg/2 ml, 0.8% hylan G-F20)
Number of subjects: 381
Study 19053964 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study 19053964 — intervention group
Group type: COMPARATOR
Intervention: Control exercise
Number of subjects: 8
Study 17388716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone (100 mg/day)
Number of subjects: 27
Study 17388716 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (2 mg/day)
Number of subjects: 27
Study 17201083 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-concentration-based system (HMS)
Number of subjects: 39
Study 17201083 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard ACT-based anticoagulation system)
Number of subjects: 39
Study 12490774 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 12490774 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 12490774 — intervention group
Group type: EXPERIMENTAL
Intervention: DIEPSS
Number of subjects: 0
Study 10368245 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL of 2% lidocaine gel administered intrarectally 15 min before biopsies (group 1)
Number of subjects: 109
Study 10368245 — intervention group
Group type: COMPARATOR
Intervention: 15 mL of trans-sonic hydrophilic gel administered transrectally (placebo, group 2)
Number of subjects: 109
Study 8683250 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cladribine 10 mg/m2/d for 5 consecutive days in monthly courses
Number of subjects: 63
Study 1913759 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (0.3 mg sublingual)
Number of subjects: 12
Study 1913759 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg orally)
Number of subjects: 12
Study 1913759 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (800 mg orally)
Number of subjects: 12
Study 1913759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6814225 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, 480 mg daily
Number of subjects: 26
Study 6814225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 30798781 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health and mental health measures
Number of subjects: 0
Study 30798781 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of crime
Number of subjects: 0
Study 30643924 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg glucagon after 45 min of cycling
Number of subjects: 14
Study 30643924 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg glucagon before cycling
Number of subjects: 14
Study 30643924 — intervention group
Group type: COMPARATOR
Intervention: Control (resting)
Number of subjects: 14
Study 27780647 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained GPs
Number of subjects: 175
Study 27780647 — intervention group
Group type: COMPARATOR
Intervention: Untrained GPs
Number of subjects: 175
Study 26377322 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (A)
Number of subjects: 600
Study 26377322 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (B)
Number of subjects: 600
Study 26377322 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy plus massage therapy (C)
Number of subjects: 600
Study 26377322 — intervention group
Group type: COMPARATOR
Intervention: Advice to stay active (D)
Number of subjects: 600
Study 23434505 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical high risk (CHR) for psychosis
Number of subjects: 53
Study 23434505 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical high risk (CHR) for psychosis with severe and psychotic symptoms (n = 10/53)
Number of subjects: 53
Study 23434505 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison (HC) subjects
Number of subjects: 53
Study 21287368 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsynchronized Nasal Intermittent Positive Pressure Ventilation
Number of subjects: 2
Study 21287368 — intervention group
Group type: COMPARATOR
Intervention: Head box oxygen, fraction of oxygen in inspired air was 50%
Number of subjects: 2
Study 19646805 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-learning video before 1-h chest compression-only CPR training
Number of subjects: 214
Study 19646805 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h chest compression-only CPR training
Number of subjects: 214
Study 19646805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-learning video)
Number of subjects: 214
Study 19646805 — intervention group
Group type: COMPARATOR
Intervention: Control group after 1-h CPR training
Number of subjects: 214
Study 17466939 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher avoidant coping
Number of subjects: 146
Study 17466939 — intervention group
Group type: COMPARATOR
Intervention: Lower avoidant coping
Number of subjects: 146
Study 15208206 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy based on estrogen receptor content
Number of subjects: 0
Study 15208206 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16200721 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean lecithin 10 g tid
Number of subjects: 542
Study 16200721 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 542
Study 16200721 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Basic treatment group)
Number of subjects: 542
Study 9635386 — intervention group
Group type: EXPERIMENTAL
Intervention: premixed insulin administered by pen
Number of subjects: 93
Study 9635386 — intervention group
Group type: COMPARATOR
Intervention: self‐mixed/syringe, premixed/syringe, self‐mixed/pen, premixed/pen
Number of subjects: 93
Study 7944878 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Chlorophenylpiperazine (MCPP) 0.1 mg/kg
Number of subjects: 22
Study 7944878 — intervention group
Group type: EXPERIMENTAL
Intervention: yohimbine hydrochloride 0.4 mg/kg
Number of subjects: 22
Study 7944878 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline solution)
Number of subjects: 22
Study 2828139 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 7
Study 2828139 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7
Study 30908879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual perfusion (DP) via both the hepatic artery and portal vein
Number of subjects: 124
Study 30908879 — intervention group
Group type: COMPARATOR
Intervention: Standard perfusion (SP) via only the portal vein
Number of subjects: 124
Study 30908879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual perfusion (DP)
Number of subjects: 124
Study 30908879 — intervention group
Group type: COMPARATOR
Intervention: Standard perfusion (SP)
Number of subjects: 124
Study 28837906 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 19
Study 28837906 — intervention group
Group type: COMPARATOR
Intervention: Balanced General Anesthesia
Number of subjects: 19
Study 25468636 — intervention group
Group type: EXPERIMENTAL
Intervention: Double low protocol (iodixanol at 270 mg iodine/ml, 100 kVp tube voltage, AIDR)
Number of subjects: 179
Study 25468636 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (iopamidol at 370 mg iodine/ml, 120 kVp tube voltage, FBP)
Number of subjects: 179
Study 24176436 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health education and access to subsidized salt substitute in 60 intervention villages.
Number of subjects: 120
Study 24176436 — intervention group
Group type: COMPARATOR
Intervention: Usual practices in control villages (30 villages).
Number of subjects: 120
Study 20821237 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID® 5 Access software (Quickview mode)
Number of subjects: 44
Study 20821237 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID® 5 Access software (auto mode and single image at 12 fps)
Number of subjects: 44
Study 20821237 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID® 5 Access software (Quickview and Quadview modes)
Number of subjects: 44
Study 20821237 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID® 5 Access software (overall)
Number of subjects: 44
Study 19264928 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive software homophone tool
Number of subjects: 0
Study 19264928 — intervention group
Group type: COMPARATOR
Intervention: Homophones highlighted only
Number of subjects: 0
Study 19264928 — intervention group
Group type: COMPARATOR
Intervention: No help
Number of subjects: 0
Study 19264928 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 17257782 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivated Stepped Care (MSC) + Contingent Voucher Incentives (CVI)
Number of subjects: 236
Study 17257782 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent Voucher Incentives (CVI)
Number of subjects: 236
Study 17257782 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivated Stepped Care (MSC)
Number of subjects: 236
Study 17257782 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 236
Study 14727206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin-pyrazinamide (RZ)
Number of subjects: 0
Study 14727206 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0
Study 14727206 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 12145595 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 100
Study 12145595 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 100
Study 10467322 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells (PBSC)
Number of subjects: 30
Study 10467322 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow (BM)
Number of subjects: 30
Study 8751023 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice taken simultaneously with felodipine
Number of subjects: 9
Study 8751023 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice taken 1 hour before felodipine
Number of subjects: 9
Study 8751023 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice taken 4 hours before felodipine
Number of subjects: 9
Study 8751023 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice taken 10 hours before felodipine
Number of subjects: 9
Study 8751023 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice taken 24 hours before felodipine
Number of subjects: 9
Study 8751023 — intervention group
Group type: COMPARATOR
Intervention: Concomitant water and felodipine intake
Number of subjects: 9
Study 8751023 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments including grapefruit juice
Number of subjects: 9
Study 8751023 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatments including grapefruit juice
Number of subjects: 9
Study 2236369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural therapy (average number of sessions: 7.2)
Number of subjects: 31
Study 2236369 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 31
Study 686894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 462
Study 686894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 686894 — intervention group
Group type: COMPARATOR
Intervention: Hexachlorophene-ethanol
Number of subjects: 462
Study 30335626 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg twice daily, n = 40)
Number of subjects: 80
Study 30335626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 80
Study 28132796 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire insertion to 15cm
Number of subjects: 69
Study 28132796 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire insertion to 17.5cm
Number of subjects: 69
Study 28132796 — intervention group
Group type: COMPARATOR
Intervention: Guidewire insertion to 20cm
Number of subjects: 69
Study 25457902 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg macitentan
Number of subjects: 742
Study 25457902 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg macitentan
Number of subjects: 742
Study 25457902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study 23660263 — intervention group
Group type: EXPERIMENTAL
Intervention: One-vessel group (n = 106)
Number of subjects: 784
Study 23660263 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-vessel group (n = 120)
Number of subjects: 784
Study 23660263 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-vessel group (n = 442)
Number of subjects: 784
Study 23660263 — intervention group
Group type: EXPERIMENTAL
Intervention: Male group
Number of subjects: 784
Study 23660263 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Logistic regression analysis
Number of subjects: 784
Study 23660263 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 116)
Number of subjects: 784
Study 21854292 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment (group counseling weeks 1-8 + transdermal nicotine patch 21 mg/day weeks 1-6; 14 mg/day weeks 7-8)
Number of subjects: 153
Study 21854292 — intervention group
Group type: COMPARATOR
Intervention: Substance abuse treatment as usual
Number of subjects: 153
Study 19703850 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct CT arthrography
Number of subjects: 126
Study 17596218 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine-propofol admixture (0.5 mg/ml ketamine in 10 mg/ml propofol)
Number of subjects: 116
Study 17596218 — intervention group
Group type: COMPARATOR
Intervention: lidocaine-propofol admixture (1 mg/ml lidocaine in 10 mg/ml propofol)
Number of subjects: 116
Study 15294063 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmicort Turbuhaler (budesonide inhalation powder) two puffs (400 microg) bid
Number of subjects: 0
Study 15294063 — intervention group
Group type: COMPARATOR
Intervention: pressurized metered-dose inhalers (pMDIs)
Number of subjects: 0
Study 11775646 — intervention group
Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 0
Study 11775646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9169397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (insulin-glucose infusion for at least 24 hours followed by multidose insulin treatment)
Number of subjects: 620
Study 9169397 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 620